Drug-resistant Shigella bacteria are becoming increasingly widespread in the United States, according to experts at the C.D.C. With infections becoming more resistant since 2013, it is difficult to control the spread of the bacteria since they can rapidly spread between people. Shigella sonnei, the main cause of bacillary dysentery in high-income countries, has become increasingly resistant to antibiotics, making it challenging to treat. The CDC warns that some strains have developed resistance to all of the standard frontline antibiotics. Additionally, some strains can spread antimicrobial resistance genes to other enteric bacteria. However, alternative antibiotics have been identified to treat Shigella, and this paper reviews the microbiology, susceptibility, efficacy, and safety of these alternatives. Concerning recommended antimicrobial drugs for Shigella, the prevalence of resistance is highest for ciprofloxacin and azithromycin. It is essential to take caution when using antibiotics to prevent further resistance. The public must be more vigilant about hygiene and prevention measures to curb the spread of the bacteria. It is important to note that research on this topic is ongoing as scientists continue to work to develop new antibiotics to combat the increasing drug-resistant strains of Shigella.
